Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Triple-tracer Molecular Imaging Using 18F-FDG, 68Ga-PSMA and 68Ga-OCTREOTATE to Characterize Metastatic Castration-resistant Prostate Cancer (mCRPC) and Evaluate Eligibility for Radionuclide Therapies

NCT04000776 is registered in ClinicalTrials.gov with Université de Sherbrooke as lead sponsor.

NCT NCT04000776
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04000776 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Triple-tracer Molecular Imaging Using 18F-FDG, 68Ga-PSMA and 68Ga-OCTREOTATE to Characterize Metastatic Castration-resistant Prostate Cancer (mCRPC) and Evaluate Eligibility for Radionuclide Therapies
Lead sponsor
Université de Sherbrooke
Phase
Observational
Overall status
Completed
Start date
December 16, 2019
Completion date
June 30, 2023
Enrollment
100 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer